Advanced search
Publication Cover
Scandinavian Journal of Infectious Diseases Volume 23, 1991 - Issue sup80
Submit an article Journal homepage
111
Views
1
CrossRef citations to date
0
Altmetric
Miscellany

HerpesVirus Infections: State of the Art

Erik Lycke
&
S. Ragnar Norrby
Pages 1-118 | Published online: 02 Jan 2015

References

  • Sakaoka H, Saito H, Sekine K, Aomori T, Grillner L, Wadell G, Fujunaga K. Genomic comparison of herpes simplex virus type 1 isolates from Japan, Sweden and Kenya. J gen Virol 68: 749–764, 1987
  • Sakaoka H, Kawana Y, Grillner L, Aomori T, Yamaguchi T, Saito H, Fujinaga K. Genome variations in herpes simplex virus type 2 strains isolated in Japan and Sweden. J gen Virol 68: 2105–2116, 1987
  • Oakes JE, Gray WL, Lausch RN. Herpes simplex virus type 1 DNA sequences which direct spread of virus from cornea to central nervous system. Virol 150: 513–517, 1986
  • Sedarati F, Stevens JG. Biological basis for virulence of three strains of herpes simplex virus type 1. J gen Virol 68: 2389–2395, 1987
  • Taha MY, Clements GB, Brown SM. The herpes simplex virus type 2 (HG52) variant has a 1488 bp deletion which eliminates neurovirulence in mice. J gen Virol 70:. 3073–3078, 1989
  • Meigner B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monleys (Aotus trivirgatus). J Inf Dis 162: 313–321, 1990
  • Bergström T, Lycke E. Neuroinvasion by herpes simplex virus. An in vitro model for characterization of neurovirulent strains. J gen Virol 71: 405–410, 1990
  • Javier RT, Sedarati F, Stevens JG. Two avirulent herpes simplex viruses generate lethal recombinants in vivo. Science 234: 746–748, 1986
  • Halliburton IW, Honess RW, Killington RA. Virulence is not conserved in recombinants between herpes simplex types 1 and 2. J gen Virol 68: 1435–1440, 1987
  • Vahlne A, Svennerholm B, Lycke E. Evidence for herpes simplex virus type-selective receptors on cellular plasma membranes. J gen Virol 44: 217–225, 1979
  • Addison C, Rixon FJ, Palfreyman JW, O'Hara M, Preston VG. Characterization of a herpes simplex virus type 1 mutant which has a temperature-sensitive defect in penetration of cells and assembly of capsids. J Virol 138: 246–259, 1984
  • Langeland N, Oyan AM, Marsden HS, Cross J, Glorioso C, Moore LJ, Haarr L. Localization on the herpes simplex virus type 1 genome of a region encoding proteins involved in adsorption to the cellular receptor. J Virol 64: 1271–1277, 1990
  • WuDunn D, Spear P. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 63: 52–58, 1989
  • Campadelli-Fiume G, Stirpe D, Boscaro A, Avitabile E, Foa-Tomasi L, Barker D, Roizman B. Glycoprotein C-dependent attachment of herpes simplex virus to susceptible cells leading to productive infection. Virology 178: 213–222, 1990
  • Lee FK, Coleman RM, Pereira L, Bailey PD, Tatsuno M, Nahmias AJ. Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J Clin Microbiol 22: 641–644, 1985
  • Löwhagen G-B, Jansen E, Nordenfelt E, Lycke E. Epidemiology of genital herpes infections in Sweden. Acta Derm Venereol (Stockh) 70: 330–334, 1990
  • Guinan ME, Wolinsky SM, Reichman RC. Epidemiology of genital herpes simplex virus infection. Epidemiol Rev 7: 127–146, 1985
  • Sacks SL. Frequency and duration of patient-observed recurrent genital herpes simplex virus infection: Characterization of the nonlesional prodrome. J Inf Dis 150: 873–877, 1984
  • Corey L, Spear P. Infections with herpes simplex viruses (Second of two parts). New Engl Med J 314: 749–757, 1986
  • Strand A, Vahlne A, Svennerholm B, Wallin J, Lycke E. Asymptomatic virus shedding in men with genital herpes infection. Scand J Infect Dis 18: 195–197, 1986
  • Corey L. First-episode, recurrent, and asymptomatic herpes simplex infections. J Am Acad Dermatol 18:. 169–172, 1988
  • Lafferty WE, Coombs RW, Benedetti J, Critchlow MS, Corey L. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. New Engl J Med 316: 1444–1449, 1987
  • Fife KH, Boggs D. Lack of evidence for intratypic recombinants in the pathogenesis of recurrent genital infections with herpes simplex virus type 1. Sex Transm Dis 13: 138–144, 1986
  • Clements GB, Subak-Sharpe JH. Herpes simplex virus type 2 establishes latency in the footpad. J gen Virol 69: 375–383, 1988
  • Claoué CMP, Hodges TJ, Darville JM, Hill TJ, Blyth WA, Easty DL. Possible latent infection with herpes simplex virus in the mouse eye. J gen Virol 71: 2385–2390, 1990
  • Craig CP, Nahmias AJ. Different patterns of neurologic involvement with herpes simplex types 1 and 2: Isolation of herpes simplex virus type 2 from the buffy coat of two adults with meningitis. J Infect Dis 127: 365–372, 1973
  • Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: Clinical manifestations, course, and complications. Ann Intern Med 98: 958–972, 1983
  • Stadler H, Oxman MN, Dawson DM, Levin MJ. Herpes simplex meningitis: Isolation of herpes simplex virus type 2 from cerebrospinal fluid. New Engl J Med 289: 1296–1298, 1973
  • Morrison RE, Miller MH, Lyon, LW, Griffis JM, Artenstein MS. Adult meningoencephalitis caused by herpesvirus hominis type 2. Am J Med 56: 540–544, 1974
  • Sköldenberg B, Jeansson S, Wolontis S. Herpes simplex virus type 2 and acute aseptic meningitis. Scand J Infect Dis 7: 227–232, 1975
  • Bergström T, Vahlne A, Alestig K, Jeansson S, Forsgren M, Lycke E. Primary and recurrent herpes simplex virus type 2-induced meningitis. J Infect Dis 162: 322–330, 1990
  • Lycke E. Biological and molecular aspects on herpes simplex virus latency. Scand J Infect Dis Suppl. 69: 113–119, 1990
  • Wagner EK, Devi-Rao P, Feldman LT, Dobson AT, Zhang Y, Flanagan WM, Stevens JG. Physical characterization of the herpes simplex latancy-associated transcript in neurons. J Virol 62: 1194–1202, 1988
  • Wechsler SL, Nesburn AB, Zwangstra J, Ghiasi H. Sequence of the latency-related gene of herpes simplex type 1. Virology 168: 168–172, 1989
  • Wilcox CL, Johnson EM Jr. Characterization of nerve growth factor-dependent herpes simplex virus latency in vitro. J Virol 62: 393–399, 1988
  • Sakaoka H, Gohro T, Sekine K, Kurita K, Fujinaga K, Kumamoto Y. Molecular-epidemiological analysis of genital herpes. VIIIth International Congress of Virology, Berlin, 1990. Abstracts p. 343
  • Klein RJ. The pathogenesis of acute, latent and recurrent herpes simplex virus infections. Brief review. Arch Virol 72: 143–168, 1982
  • Vahlne A, Nilheden E, Svennerholm B. Multiplicity of activation of herpes simplex virus in mouse neuroblastoma (C1300) cells. Arch Virol 70: 345–356, 1981
  • Lycke E, Kristensson K, Svennerholm B, Vahlne A, Ziegler R. Uptake and transport of herpes simplex virus in neurites of rat dorsal root ganglia cells in culture. J gen Virol 65: 55–64, 1984
  • Lycke E, Hamark B, Johansson M, Krotochvil A, Lycke J, Svennerholm B. Herpes simplex virus infection of the human sensory neuron. An electron microscopy study. Arch Virol 101: 87–104, 1988
  • Para MF, Baucke RB, Spear PG. Immunoglobulin G(Fc)-binding receptors on virions of herpes simplex type 1 and transfer of these receptors to the cell surface by infection. J Virol 34: 512–520, 1980
  • Friedman HM, Cohen GH, Eisenberg RJ, Seidel CA, Cines DB. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Nature (London) 309: 633–635, 1984
  • McNearney TA, Odell C, Holers VM, Spear PG, Atkinson JP. Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity. J Exp Med 166: 1525–1535, 1987
  • Mindel A. In Herpes simplex virus. The Bloomsbury series in clinical virology. Springer-Verlag, Berlin and Heidelberg, 1989
  • Maehlen J, Daa Schröder H, Klareskog L, Olsson T, Kristensson K. Axotomy induces MHC class I antigen expression on rat nerve cells. Neuroscience letters 92: 8–13, 1988
  • Olsson T, Maehlen J, Löve A, Klareskog L, Norrby E, Kristensson K. Induction of class I and class II transplantation antigens in rat brain during fatal and non-fatal measles virus infection. J Neuroimmunol 16: 215–224, 1987
  • Gairin JE, Joly E, Oldstone MBA. Modulation of MHC class I expression on mouse brain endothelial cells by lymphocytic choriomeningitis virus. VIIIth International Congress of Virology. Berlin, 1990. Abstracts p. 150
  • Svennerholm B, Ziegler R, Lycke E. Herpes simplex virus infection of the rat sensory neuron. Effects of interferon on cultured cells. Arch Virol 104: 153–156, 1989

References

  • Frenkel N, Schirmer EC, Wyatt LS, Katsafanas G, Roffman E, Danovich RM, and June CH. Isolation of a new herpesvirus from human CD4+ T-cells. Proc Natl Acad Sci USA 87: 748, 1990
  • Nahmias AJ, Keyserling H, Lee FK. Herpes simplex viruses 1 and 2. In: Evans AS, ed.Viral Infections of Humans. Epidemiology and control: New York and London: Plenum. 393–417, 1989
  • Spruance SL, Overall JC, Kern ER, Kreuger GC, Pliam V, Miller W. The natural history of recurrent herpes simplex labialis. N Engl J Med 297: 69–75, 1977
  • Dawson CR, Togni B. Herpes simplex eye infections. Clinical manifestations, pathogenesis and management. Surv Ophthalmol 21: 121, 1976
  • Darougar S, Wishart MS, Viswalingham ND. Epidemiological and clinical features of primary herpes simplex virus ocular infection. Br J Ophthalmol 69: 2–6, 1985
  • Sköldenberg B, Forsgren M, Alestig K, Bergström T, Burman L, Dahlqvist E, Forkman A, Frydvgren K, Norlin K, Norrby R, Olding-Stenkvist E, Stiernstedt G, Uhnoo I, de Vahl K. Acyclovir versus vidarabine in herpes simplex encephalitis. Lancet II: 707–711, 1984
  • Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias AJ, Soong, SJ. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 314: 144–149, 1986
  • Whitley RJ. Viral encephalitis. N Engl J Med 323: 242–250, 1990
  • Masur H. Infections in homosexual men. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases 3rd. ed. New York: Churchill Livingstone. 2280–2284, 1990
  • Nahmias AJ, Keyserling HH, Kerrick G. Herpes simplex. In: Remington JS, Klein JO, eds. Infectious Diseases of the fetus and newborn infant. Philadelphia: WB Saunders, 156–190, 1983
  • Sullivan-Bolyai J, Hull HF, Wilson C, Corey L. Neonatal herpes simplex virus infection in King County, Washington. Increasing incidence and epidemiologic correlates. JAMA 250: 3059–3062, 1983
  • Gäbel H, Flamholc L, Ahlfors K. Herpes simplex virus hepatitis in a renal transplant recipient: Successful treatment with acyclovir. Scand J Infect Dis 20: 435–438, 1988
  • Weller TH, Varicella-zoster virus. In: Evans AS, ed.Viral infections of humans. Epidemiology and control. New York: Plenum, 659–683, 1989
  • Hope-Simpson RE. The Nature of herpes zoster. A long term study and a new hypothesis. Proc Roy Soc Med 58: 9–20, 1965
  • Peterslund NA. Management of varicella zoster infections in immunocompetent hosts. Am J Med 85 ( Suppl 2A): 74–78, 1988
  • Jensen PK, Andersen EB, Boesen F, Dissing I, Vestergaard BF. The incidence of herniated disc and varicella zoster virus infection in lumboradicular syndrome. Acta Neurol Scand 80: 142–144, 1989
  • Gallagher JG, Merigan TC. Prolonged Herpes zoster infection associated with immunosuppressive therapy. Ann Int Med 91: 842–846, 1979
  • Sullivan JL, Woda BA, Herrod HG, Koh G, Rivara FP, Mulder C. Epstein-Barr virus-associated haemophagocytic syndrome: Virological and immunopathological studies. Blood 65: 1097–1104, 1985
  • Yamanishi K, Shiraki K, Kondo T, Okuno T, Takahashi M, Asano Y, Kurata T. Identification of human herpesvirus-6 as a causal agent for exanthema subitum. Lancet 1: 1065–1067, 1988
  • Levy JA, Greenspan D, Ferro F, Lennette ET. Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population. Lancet 335: 1047–1050, 1990
  • Huang LM, Lee CY, Lin KH, Chuu WM, Lee PI, Chen RL, Chen JM, Lin DT. Human Herpesvirus-6 associated with fatal haemophagocytic syndrome. Lancet 2: 60–61, 1990

References

  • Baldwin S, Whitley RJ. Intrauterine HSV infection. J Teratology 39: 1–10, 1988
  • Florman AL, Gershon AA, Blackett PR, Nahmias AJ. Intrauterine infection with herpes simplex virus: Resultant congenital malformations. JAMA 225: 129–132, 1973
  • Hanshaw JW. Herpesvirus hominis infections in the fetus and newborn. Am J Dis Child 126: 546–555, 1973
  • Hutto C, Arvin A, Jacobs R. Intrauterine herpes simplex virus infections. J Pediatr 110: 97–101, 1987
  • South MA, Tompkins NA, Morris CR, Rawls WE. Congenital malformation of the central nervous system associated with genital type (type 2) herpesvirus. J Pediatr 75: 8–13, 1969
  • Gagnon A. Transplacental inoculation of fetal herpes simplex in the newborn. Obstet Gynecol 31: 682–684, 1968
  • Witzleben CL, Driscoll SC. Possible transplacental transmission of herpes simplex infection. Pediatrics 36: 192–199, 1965
  • Whitley RJ. Herpes simplex viruses. In Fields BN, Knipe DM (Eds). Fields Virology, 2nd Ed. New York: Raven Press: 1865, 1990
  • Whitley RJ, Arvin A, Prober C, Burchett S, Corey L, Powell D, Plotkin S, Starr S, Alford C, Connor J, Jacobs R, Nahmias A, Soong S-J and the N.I.A.I.D. Collaborative Antiviral Study Group. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Eng J Med 324: 333–339, 1991
  • American Academy of Pediatrics. Perinatal herpes simplex virus infections. Committee on Fetus and Newborn and Infectious Diseases. Pediatrics 66: 147–148, 1980
  • Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB. A seroepidemiological survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Eng J Med 321: 7–12, 1989
  • Ades AE, Peckham CS, Dale GE, Best JM, Jeansson S. Prevalence of antibodies to herpes simplex virus types 1 and 2 in pregnant women and estimated rates of infection. J Epid Comm Health 43: 53–60, 1989
  • Nahmias AJ, Keyserling HL, Kerrick CM. Herpes simplex: In: Remington JS, Klein JO, (Eds). Infectious Diseases of the Fetus and Newborn. Philadelphia: WB Saunders: 638, 1983
  • Whitley RJ. Herpes simplex virus infections. In: Klein JO, Remington JS, (Eds). Infectious Diseases of the Fetus and Newborn. Philadelphia: WB Saunders 1987
  • Whitley RJ, Nahmias AJ, Visintine AM, Fleming CL, Alford CA. The natural history of herpes simplex virus infection of mother and newborn. Pediatrics 66: 489–494, 1980
  • Lissauer TJ, Shaw PJ, Underhill G. Neonatal herpes simplex pneumonia. Arch Dis Child 59: 668–670, 1984
  • Binkin NJ, Kaplan JP, Cates W. Preventing neonatal herpes. JAMA 251: 2816–2821, 1984
  • Whitley RJ, Corey L, Arvin A and the N.I.A.I.D. Collaborative Antiviral Study Group. Changing presentation of herpes simplex virus infection in neonates. J Infect Dis 158: 109–116, 1988
  • Arvin AM, Hensleigh PA, Prober CG. Failure of antepartum maternal cultures to predict the infant's risk of exposure to herpes simplex virus at delivery. N Eng J Med 315: 796–800, 1986
  • Prober CG, Sullender WM, Yasukawa LL, Au DS, Yeager AS, Arvin AM. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Eng J Med 316: 240–244, 1987
  • Prober CG, Hensleigh PA, Boucher FD, Yasukawa LL, Au DS, Arvin AM. Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. N Eng J Med 318: 887–891, 1988
  • Brown ZA, Vontver LA, Benedetti J, Critchlow CW, Sells CJ, Berry S, Corey L. Effects on infants of a first episode of genital herpes during pregnancy. N Eng J Med 317: 1246–1251, 1987
  • Lissauer T, Jeffries DJ. Preventing neonatal herpes infection. Br J Obst Gynaec. 96: 1015–1023, 1989
  • Andrews EB, Tilson HH, Hurn BAL, Cordero JF. Acyclovir in pregnancy registry. Am J Med 85 ( Supp 2A): 123–128, 1988
  • Grint P. Personal communication 1991
  • Brocklehurst P, Carney O, Helson K, Kinghorn G, Mercey D, Mindel A. Acyclovir, herpes and pregnancy. Lancet 336: 1595–1596, 1990
  • Douglas J, Schmidt O, Corey L. Acquisition of neonatal HSV-1 infection from a paternal source contact. J Pediatr 103: 908–910, 1983
  • Dunkle LM, Schmidt RR, O'Connor DM. Neonatal herpes simplex infection possibly acquired via maternal breast milk. Pediatrics 63: 250–251, 1979
  • Francis DP, Hermann KL, MacMahon JR, Chivigny KH, Sanderlin KC. Nosocomial and maternally acquired herpesvirus hominis infections, a report of four fatal cases in neonates. Am J Dis Child 129: 889–893, 1975
  • Hammerberg O, Wahs J, Chernesky M, Luchsinger I, Rawls W. An outbreak of herpes simplex virus type 1 in an intensive care nursery. Pediatr Infect Dis 2: 290–294, 1983
  • Light IJ. Postnatal acquisition of herpes simplex virus by the newborn infant: A review of the literature. Pediatrics 63: 480–482, 1979
  • Linnemann CC, Buchman TG, Light IJ, Ballard JL, Roizman B. Transmission of herpes simplex virus type 1 in a nursery for the newborn: Identification of viral species isolated by DNA fingerprinting. Lancet 1: 964–966, 1978

References

  • Mindel A, Coker DM, Faherty A, Williams P. Recurrent genital herpes: Clinical and virological features in men and women. Genitourin Med 64: 103–106, 1988
  • Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infection clinical manifestations, cause and complications. Ann Intern Med 98: 958–972, 1983
  • Adler MW, Mindel A. Genital infection. In: British Medical Bulletin 41: 361–366, 1985
  • Corey L. Genital herpes simplex virus infection: Natural history and therapy. In: Recent Advances in Sexually Transmitted Diseases. Eds Oriel JA, Harries JRW. Edinburgh Churchill Livingston 71–108, 1986
  • Mindel A, Adler MW, Sutherland S, Fiddian AP. Intravenous acyclovir treatment for primary genital herpes. Lancet i: 697–700, 1982
  • Bryson YJ, Dillon M, Lovett M . Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. N Engl Med 308: 916–921, 1983
  • Nilsen AE, Aasen T, Halsos Am, Kinge BR, Tjotta EAL, Wikstrom K, Fiddian AP. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet ii: 571–573, 1982
  • Corey L, Mindel A, Fife KH, Sutherland S, Benedetti J, Adler MW. Risk of recurrence after treatment of first episode genital herpes with intravenous acyclovir. Sex Trans Dis 12: 215–218, 1985
  • Corey L, Nahmias AJ, Guinan ME, Benedetti JK, Critchlow CW, Holmes KK. A trial of topical acyclovir in genital herpes virus infections. N Engl Med 306: 1313–1319, 1982
  • Mertz GJ, Critchlow CW, Benedetti J, Reichman RC, Dolin R, Connor J, Redfield DC, Savoia MC, Richman DD, Tyrrell DL, Miedzinski L, Portnoy J, Keeney RE, Corey L. Double blind placebo-controlled trial of oral acyclovir in first episode genital herpes simplex virus infection. JAMA 252: 1147–1151, 1984
  • Fiddian AP, Yeo JM, Stubbings R, Dean D. Successful treatment of herpes labialis with topical acyclovir. Br Med J 286: 1699–1700, 1983
  • Raborn GW, McGaw WT, Grace M, Percy J. Treatment of herpes labialis with acyclovir: Review of three clinical trails. Am J Med 85 ( Suppl. 2A): 39–42, 1988
  • Elion GB. Mechanism of action and selectivity of acyclovir. Am J Med 73 ( Suppl. 1A): 7–13, 1982
  • Reichman RC, Badger GJ, Mertz GJ, . Treatment of recurrent genital herpes simplex infection with oral acyclovir, a controlled trial. JAMA 251: 2103–2107, 1984
  • Thin RN, Jeffries DJ, Taylor PK, Arya OP, Rodin P, Yeo J, Fiddian AP. Recurrent genital herpes suppressed by oral acyclovir: A multicentre double-blind trial. J Antimicrob Chemother 16: 219–226, 1985
  • Douglas JM, Critchlow C, Benedetti J, . A double-blind study of oral acyclovir for suppression of recurrence of genital herpes simplex virus infection. N Engl J Med 310: 1551–1556, 1984
  • Straus SE, Takiff HE, Seidlin M, . Suppression of frequently recurring genital herpes. A placebo controlled double-blind trial of oral acyclovir. N Engl J Med 310: 1545–1550, 1984
  • Mindel A, Weller IVD, Faherty A, . Prophylactic oral acyclovir in recurrent genital herpes. Lancet ii: 57–59, 1984
  • Tilson HH. Monitoring the safety of antivirals. The example of the acyclovir experience. Am J Med 85 ( Suppl. 2A): 116–122, 1988
  • Mindel A, Faherty A, Carney O, Patou G, Freris M, Williams P. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet i: 926–928, 1988
  • Straus SE, Goen KD, Sawyer MH, . Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment. JAMA 260: 2227–2230, 1988
  • Kroon S, Petersen CS, Andersen LP, Ronne Rasmussen J, Vertergaard BF. Long-term suppression of severe recurrent genital herpes simplex infection with oral acyclovir: A dose titration study. Genitourin Med 66: 101–104, 1990
  • Mindel A, Carney O. Acyclovir malabsorption. Br Med J 296: 1605, 1988

References

  • Bryson YJ. Current status and prospect for oral acyclovir treatment of first episode and recurrent genital herpes simplex virus. J Antimicrob Chemother 12 ( Suppl B): 61–69, 1983
  • Salo OP, Lassus A, Hovi T, Fiddian AP. Double-blind placebo-controlled trial of oral acyclovir in recurrent genital herpes. Eur J Sex Transm Dis 1: 101–105, 1983
  • Nilsen AE, Aasen T, Halsos AM, Kinge BR, Tjotta EAL, Wikström K, Fiddian AP. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet ii: 571–573, 1982
  • Douglas JM, Critchlow CL, Benedetti J, Mertz GT, Connor JD, Hintz MA, Fahlander A, Remington M, Winter C, Corey L. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 310: 1551–1556, 1984
  • Strauss SE, Takiff HE, Seidlin M, Bachrach S, Lininger L, DiGiovanna JJ, Western KA, Smith HA, Lehrman, SN, Creagh-Kirk T, Alling AW. Suppression of frequently recurring genital herpes: A placebo-controlled double-blind trial of oral acyclovir. N Engl J Med 310: 1545–1550, 1984
  • Mindel A, Weller IVD, Faherty A, Sutherland S, Hindley D, Fiddian AP, Adler MW. Prophylactic oral acyclovir in recurrent genital herpes. Lancet ii: 57–59, 1984
  • Halsos AM, Salo OP, Lassus A, Tjotta AL, Hovi T, Gabrielsen BO, Fiddian AP. Oral acyclovir suppression of recurrent genital herpes. Acta Derm Venereol (Stockholm) 65: 59–63, 1985
  • Molin L, Bäck O, Frödin T, Svennerholm B. Long-term twice-daily oral acyclovir therapy suppresses frequently recurrent genital herpes. Scand J Infect Dis 19: 273–274, 1986
  • Mertz GJ, Jones CC, Mills J. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. JAMA 260: 201–206, 1988
  • Baker DA, Blythe JG, Kaufman R, Hale R, Portnoy J. One-year suppression of frequently recurrences of genital herpes with oral acyclovir. Obstet gynecol 73: 84–87, 1989
  • Mindel A, Faherty A, Carney O, Patou G, Freris M, Williams P. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet i: 926–928, 1988
  • Kroon S, Petersen CS, Andersen LP, Ronne-Rasmussen J, Vestergaard BF. Long-term suppression of severe recurrent genital herpes simplex infections with oral acyclovir: A dose-titration study. Genitourin Med 66: 101–104, 1990
  • Nilheden E, Jeansson S, Vahlne A. Typing of herpes simplex virus by an enzyme-linked immunosorbent assay with monoclonal antibodies. J Clin Microbiol 17: 667–680, 1983
  • Svennerholm B, Vahlne A, Löwhagen GB, Widell A, Lycke E. Sensitivity of HSV strains isolated before and after treatment with acyclovir. Scand J Infect Dis suppl 47: 149–154, 1985
  • Jeansson S, Forsgren M, Svennerholm B. Evaluation of solubilized herpes simplex virus membrane antigen by enzyme-linked immunosorbent assay. J Clin Microbiol 18: 1160–1166, 1983
  • Svennerholm B, Olofsson S, Jeansson S, Vahlne A, Lycke E. Herpes simplex virus type-selective enzyme-linked immunosorbent assay with helix pomatia lectin-purified antigens. J Clin Microbiol 19: 235–239, 1984
  • Forghani G, Schmidt NJ, Dennis J. Antibody assays for varicella-zoster virus: Comparison of enzyme immunoassay with neutralization, immune adherence hemagglutination, and complement fixation. J Clin Microbiol 8: 545–552, 1978
  • Krishna RV, Meurman OH, Ziegler T, Krech UH. Solid-phase enzyme immunoassay for determination of antibodies to cytomegalovirus. J Clin Microbiol 12: 46–51, 1980
  • Husinoff-Lehrman S, Douglas JM, Corey L, Barry DW. Recurrent genital herpes and suppressive oral acyclovir therapy. Relationship between clinical outcome and in vitro drug sensitivity. Ann Intern Med 1986; 104: 786–790
  • Straus SF, Seidlin M, Takiff HE, Rooney JF, Lerman SN, Bachrach S, Felser JM, DiGiovanna JJ, Grimes GJ, Krakauer H. Double-blind comparision of weekend and daily regimens of oral acyclovir for suppression of recurrent genital herpes. Antiviral Res. 6: 151–159, 1986
  • Gold D, Ashley R, Solberg G, Abbo H, Corey L. Chronic-dose acyclovir to suppress frequently recurring genital herpes simplex infection: Effect on antibody response to herpes simplex virus type 1 proteins. J Infect Dis 158: 1217–1234, 1988

References

  • Johnson RT, Olson LC, Buescher EL. Herpes simplex virus infection of the nervous system. Arch Neurol 18: 260–263, 1968
  • Whitley RJ, Soong S-J, Dolin R, Galasso GJ, Ch'ien LT, Alford CA, and the Collaborative Antiviral Study Group. Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. N Engl J Med: 297: 289–294, 1977
  • Bos CA, Olding-Stenkvist E, Wilterdink JB, Scheffer AJ. Detection of viral antigens in cerebrospinal fluid of patients with herpes simplex encephalitis. J Med Virol 21: 169–178, 1987
  • Lakeman FD, Koga J, Whitley RJ. Detection of antigen to herpes simplex virus in cerebrospinal fluid from patients with herpes simplex encephalitis. J Infect Dis 155: 117–178, 1987
  • Levine DP, Laute CB, Lerner AM. Simultaneous serum and CSF antibodies in herpes simplex virus encephalitis. JAMA 240: 356–360, 1978
  • Forsgren M, Sköldenberg B, Jeansson S, Grandien M, Blomberg J, Juto P, Bergström T, Olding-Stenkvist E. Serodiagnosis of herpes encephalitis by indirect enzyme-linked immunosorbent assay, experience from a Swedish antiviral trial. Serodiagn Immunother Infect Dis 3: 259–271, 1989
  • Aurelius E, Forsgren M, Skoog E, Sköldenberg B. Serodiagnosis of herpes simplex encephalitis by antibody capture enzyme-linked immunosorbent assay. Serodiagn Immunother Infect Dis 3: 249–258, 1989
  • Vandvik B. Sköldenberg B, Forsgren M, Stiernstedt G, Jeansson S, Norrby E. Long-term persistence of intrathecal virus-specific antibody response after herpes simplex encephalitis. J Neurol 231: 307–312, 1985
  • Aurelius E, Johansson B, Sköldenberg B, Staland Å, Forsgren M. Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet 337: 189–192, 1991
  • Aurelius E, Forsgren M, Sköldenberg B. Long-term persistence of increased levels in cerebrospinal fluid of neopterin and β2-microglobulin after herpes simplex encephalitis. Manuscript.
  • Sköldenberg B, Forsgren M, Alestig K, Bergström T, Burman L, Dahlqvist F, Forkman A, Frydén A, Lövgren K, Norlin K, Norrby R, Olding-Stenkvist E, Stiernstedt G, Uhnoo I, de Vahl K. Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet 2: 707–711, 1984
  • Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, Hanley D, Nahmias AJ, Soong S-J, the N.I.A.I.D. Collaborative Antiviral Study Group. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 314: 144–149, 1986
  • Sköldenberg B, Forsgren M and the Collaborative Swedish Herpes Encephalitis Study Group. Acyclovir versus vidarabine in herpes simplex encephalitis. Scand J Infect Dis, Suppl 47: 89–96, 1985
  • Hindmarsh T, Lindkvist M, Olding-Stenkvist E, Sköldenberg B. Accuracy of computer tomography in the diagnosis of herpes simplex encephalitis. Acta Radiol 209: 192–196, 1986
  • Gordon B, Selnes OA, Hart J Jr, Haneley DF, Whitley RJ. Long-term cognitive sequelae of acyclovir-treated herpes simplex encephalitis. Arch Neurol 47: 646–647, 1990

References

  • Stern H, Elek SO, Millar OM, Anderson HF. Herpetic Whitlow: A Form of Cross-Infection in Hospitals. Lancet ii: 871–874, 1959
  • Sehayik RI, Bassett FH. Herpes simplex infection involving the hand. Clin Orthop 166: 138–140, 1982
  • Selling B, Klbrick S. An outbreak of herpes simplex among wrestlers (Herpes gladiatorum). N Engl J Med 270: 979–982, 1964
  • Porter PS, Baughman RD. Epidemiology of herpes simplex among wrestlers. JAMA 194: 998–1000, 1965
  • Wheeler CEJ, Cabaniss WH Jr. Epidemic cutaneous herpes simplex in wrestlers (Herpes gladiatorum). JAMA 194: 993–997, 1965
  • Feder HM, White WB. Herpes simplex virus infections. New Engl J Med 316: 754–755, 1987
  • Gill MJ, Arlette J, Buchan K. Herpes simplex virus infection of the hand. Am J Med 84: 89–93, 1988
  • Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections. Clinical manifestations, course and complications. Ann Intern Med 98: 958–972, 1983
  • Mindel A, Carney O, Williams P. Cutaneous herpes simplex infections. Genitourin Med 66: 14–15, 1990
  • Müller SA, Herrman EC, Winkelmann RK. Herpes simplex infection in haematalogical malignancies. Am J Med 52: 102–114, 1972
  • Logan WS, Tindall JP, Elson ML. Chronic cutaneous herpes simplex. Arch Dermatol 103: 606–614, 1971
  • Siegal F, Lopez C, Hammer GS, Brown AE, Kornfeld SJ, Gold J, Hassett J, Hirshman SZ, Cunningham-Rundles C, Adelsberg BR, Parkham DM, Seigal M, Cunningham-Rundles S, Armstrong D. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 305: 1439–1444, 1981
  • Scheidman DW, Barr RJ, Graham JH. Chronic cutaneous herpes simplex JAMA 241: 592–594, 1979
  • Gold JWM. Clinical spectrum of infection in patients with HTLV-III associated disease. Cancer Res 45: 4652–4654, 1985
  • Mildvan D, Mathur U, Enslow RW, Romain PL, Winchester RJ, Colp C, Singham H, Adelsberg BR, Spigland I. Opportunistic infection and immune deficiency in homosexual men. Ann Intern Med 96: 700–704, 1982
  • Lynfield YL, Farhangi M, Runnels JL. Generalised herpes simplex complicating lymphoma. JAMA 207: 944–945, 1969
  • Rendtorff RC, Fowinkle EW. Herpes simplex skin lesions simulating smallpox. JAMA 192: 998–1000, 1964
  • Smith KO, Melnick JL. Recognition and quantitation of herpes virus particles in human vesicular lesions. Science 137: 543–544, 1962
  • Solomon M. Herpes simplex virus from skin lesions of myelogenous leukaemia. Arch Intern Med 107: 100–104, 1961
  • St Geme JW, Prince JT, Burke BA, Good RA, Krivit W. Impaired cellular resistance to herpes simplex virus and varicella zoster infections. N Engl J Med 273: 229–234, 1970
  • Wheeler CE, Abele DC, Hill C. Eczema herpeticum primary and recurrent. Arch Dermatol 93: 162–173, 1966
  • Ogilvie MM, Kesseler M, Leppard BJ, Goodwin P, White JE. Herpes simplex infections in pemphigus: An indication for urgent virual studies and specific antiviral therapy. Br J Dermatol 109: 611–613, 1983
  • Higgins PG, Crow KD. Recurrent Kaposi's varicelliform eruption in Darier's disease. Br J Dermatol 88: 391–394, 1973
  • Silverstein EH, Burnett JW. Kaposi's varicelliform eruption complicating pemphigus foliaceous. Arch Dermatol 95: 214–216, 1967
  • Verbov J, Munro DP, Miller A. Recurrent eczema herpeticum associated withy ichthyosis vulgaris. Br J Derm 86: 638–640, 1972
  • Fitzgerald WC, Booker AP. Congential ichthyosiform erythroderma. A case report of cases in siblings, one complicated by Kaposi's varicelliform eruption. Arch Derm Syph 65: 611–619, 1951
  • David TJ, Longson M. Herpes simplex infections in atopic eczema. Arch Dis Child 60: 338–343, 1985
  • Leyden JJ, Baker DA. Localised herpes simplex infections in atopic dermatitis. Arch Dermatol 115: 311–312, 1979
  • Atherton DJ, Marshall WC. Eczema herpeticum. Practitioner 226: 971–973, 1982
  • Wenner HA. Complications of infantile eczema caused by the virus of herpes simplex. Am J Dis Child 4: 247–264, 1944
  • Mailman CJ, Miranda JL, Speck A. Recurrent eczema herpeticum. Arch Dermatol 89: 815–818, 1964
  • Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: A critical review of characteristics, diagnostic criteria and causes. J Am Acad Dermatol 8: 763–775, 1983
  • Bean SF, Quezada RK. Recurrent oral erythema multiforme: Clinical experince with 11 patients. JAMA 249: 2810–2812, 1983
  • MacDonald A, Feiwel M. Isolation of herpes virus from erythema multiforme. Br Med J 2: 570–571, 1972
  • Britz M, Sibulkin D. Recurrent erythema multiforme and herpes genitalia (type 2). JAMA 233: 812–813, 1975
  • Orton PW, Huff JC, Toneson MG, Weston WC. Detection of a herpes viral antigen in skin lesions of erythema multiforme. Ann Intern Med 101: 48–50, 1984

References

  • Hope-Simpson RE. The nature of herpes zoster: A long-term study and a new hypothesis. Proc Roy Soc Med 58: 9–20, 1965
  • Gilden DH, Vafai A, Shtram Y, Becker Y, Devlin M, Wellish M. Varicella-zoster virus DNA in human sensory ganglia. Nature 306: 478–480, 1983
  • Mahalingam R, Wellish M, Wolf W, Dueland AN, Cohrs R, Vafai A, Gilden D. Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia. N Engl J Med 323: 627–631, 1990
  • Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: Clinical review and current management. Ann Neurol 20: 651–664, 1986
  • Burgoon CF, Burgoon JS, Baldridge GD. The natural history of herpes zoster. JAMA 164: 265–269, 1957
  • de Moragas JM, Kierland RR. The outcome of patients with herpes zoster. AMA Arch Dermatol 75: 193–196, 1957
  • Huff JC, Bean B, Balfour HH Jr, Laskin OL, Connor JD, Corey L, Bryson YJ, McGuirt P. Therapy of herpes zoster with oral acyclovir. Am J Med 85 ( Suppl 2A): 84–89, 1988
  • Wood MJ, Ogan PH, McKendrick MW, Care CD, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 85 ( Suppl 2A): 79–83, 1989
  • Rusthoven JJ, Ahlgren P, Elhakim T, Pinfold P, Reid J, Stewart L, Feld R. Varicella-zoster infection in adult cancer patients. A population study. Arch Intern Med 148: 1561–1566, 1988
  • Whitley RJ, Soong S-J, Dolin R, Betts R, Linnemann C Jr, Alford CA Jr and the N.I.A.ID. Collaborative Antiviral Study Group. Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med 307: 971–975, 1982
  • Head H, Campbell AW. The pathology of herpes zoster and its bearing on sensory localization. Brain 23: 353–523, 1900
  • Müller SA, Winkelmann RK. Cutaneous nerve changes in zoster. J Invest Dermatol 52: 71–77, 1969
  • Wildenhoff KE, Esmann V, Ipsen J, Harving H, Peterslund NA, Schönheyder H. Treatment of trigeminal and thoracic zoster with idoxuridine. Scand J Infect Dis 13: 257–262, 1981
  • Cobo LM, Foulks GN, Liesegang T, Lass J, Sutphin JE, Wilhelmus K, Jones DB, Chapman S, Segreti AC, King DH. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 93: 763–770, 1986
  • Bhala BB, Ramamoorthy C, Bowsher D, Yelnoorker KN. Shingles and post herpetic neuralgia. Clinical Journal of Pain 4: 169–174, 1988
  • Hope-Simpson RE. Post-herpetic neuralgia. J Royal Coll Gen Pract 25: 571–575, 1975
  • Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine 62: 310–316, 1982
  • Schmader KE, Studenski S. Are current therapies useful for the prevention of postherpetic neuralgia? A critical analysis of the literature. J Gen Intern Med 4: 83–89, 1989
  • Wildenhoff KE, Ipsen J, Esmann V, Ingemann-Jensen J, Poulsen JH. Treatment of herpes zoster with idoxuridine ointment including a multivariate analysis of symptoms and signs. Scand J Infect Dis 11: 1–9, 1979
  • Noordenbos W. Problems Pertaining to the Transmission of Nerve Impulses Which Give Rise to Pain: Preliminary Statement. Amsterdam, Elsevier Science Publishers, 1959, p. 182.
  • McKendrick MW McGill JI Wood MJ. Lack of effect of acyclovir on postherpetic neuralgia. Br Med J 298: 431, 1989
  • Peterslund NA, Seyer-Hansen K, Ipsen J, Esmann V, Schönheyder H, Juhl H. Acyclovir in herpes zoster. Lancet ii: 827–830, 1981
  • Locksley RM, Fluornoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 152: 1172–1181, 1985
  • Merigan TC, Rand KH, Pollard RB, Abdullah PS, Jordan GW, Fried RP. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med 298: 981–987, 1978
  • Zacks SI, Langfitt TW, Elliott FA. Herpetic neuritis: A light and electron microscopic study. Neurology 14, 744–750, 1964
  • Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in post herpetic neuralgia. Neurology 32: 671–673, 1982
  • Schon F, Mayer ML, Kely JS. Pathogenesis of post-herpetic neuralgia. Lancet ii: 366–368, 1987
  • Scott TFM. Herpes zoster and chicken-pox. In: Modern practice in infectious fevers. Banks HS (Ed), London, Butterworth, 1951
  • Colding A. The effect of sympathetic blocks on herpes zoster. Acta Anaesthesiol Scand 13: 113–141, 1969
  • Dawber R. Idoxuridine in herpes zoster: Further evaluation of intermittent topical therapy. Br Med J 2: 526–527, 1974
  • Juel-Jensen BE, MacCallum FO, MacKenzie AMR, Pike MC. Treatment of zoster with idoxuridine in dimethyl sulphoxide. Results of two double-blind controlled trials. Br Med J 4: 776–780, 1970
  • Sklar SH, Blue WT, Alexander EJ, Bodian CA. Herpes zoster. The treatment and prevention of neuralgia with adenosine monophosphate. JAMA 253: 1427–1430, 1985
  • Sherlock CH, Corey L. Adenosine monophosphate for the treatment of varicella zoster infections: A large dose of caution. JAMA 253: 1444–1445, 1985
  • Galbraith AW. Treatment of acute herpes zoster with amantadine hydrochloride (Symmetrel). Br Med J 4: 693–695, 1973
  • Balfour HH Jr, Bean B, Laskin OL, Ambinder RF, Meyers JD, Wade JC, Zaia JA, Aeppli D, Kirk LE, Segreti AC, Keeney RE, and the Burroughs Wellcome Collaborative Acyclovir Study Group. N Engl J Med 308: 1448–1453, 1983
  • Bean B, Braun C, Balfour HH Jr. Acyclovir therapy for acute herpes zoster. Lancet 2: 118–121, 1982
  • van den Broek PJ, van der Meer JWM, Mulder JD, Versteeg J, Mattie H. Limited value of acyclovir in the treatment of uncomplicated herpes zoster: A placebo-controlled study. Infection 12: 338–341, 1984
  • McKendrick MW, Care C, Burke C, Hickmott E, McKendrick GDW. Oral acyclovir in herpes zoster. J Antimicrob Chemother 14: 661–665, 1984
  • Wassilew SW, Reimlinger S, Nasemann T, Jones D. Oral acyclovir for herpes zoster: A double-blind controlled trial in normal subjects. Brit J Dermatol 117: 495–501, 1987
  • Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. New Zealand Med J 102: 93–95, 1989
  • Epstein E. Treatment of herpes zoster and postzoster neuralgia by subcutaneous injection of triamcinolone. Int J Dermatology 20: 65–68, 1981
  • Keczkes K, Basheer AM. Do corticosteroids prevent post-herpetic neuralgia? Br J Dermatology 102: 551–555, 1980
  • Eaglstein WH, Katz R, Brown JA. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA 211: 1681–1683, 1970
  • Esmann V, Geil JP, Kroon S, Fogh H, Peterslund NA, Petersen CS, Rønne-Rasmussen JO, Danielsen L. Prednisolone does not prevent post-herpetic neuralgia. Lancet 2: 126–129, 1987
  • Watson PN, Evans RJ. Postherpetic neuralgia. A review. Arch Neurol 43: 836–840, 1986
  • Gersen GR, Jones RB, Luscombe DK. Studies on the concomitant use of carbamazepine and clomipramine for the relief of postherpetic neuralgia. Postgrad Med J 54 ( Suppl 4): 104–109, 1977

References

  • Burgoon CF, Burgoon JS, Baldridge GD. The natural history of herpes zoster. J Am Med Assoc 164: 265–269, 1957
  • De Moragas JM, Keirland RR. The outcome of patients with herpes zoster. Am Med Assoc Arch Dermatol 75: 193–196, 1957
  • Wood MJ, Ogan PH, McKendrick MW, Care CD, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 85 ( S2A): 79–83, 1988
  • Jolleys JV. Treatment of shingles and post-herpetic neuralgia. Br Med J 298: 1537–1538, 1989
  • Crooks RJ, Bell AR, Fiddian AP. Treatment of shingles and post-herpetic neuralgia. Br Med J 299: 392–393, 1989
  • Jolleys JV. Author's reply. Br Med J 299: 392–393, 1989
  • Crooks RJ, Bell AR, Fiddian AP. Treatment of shingles and post-herpetic neuralgia. Br Med J 299: 740, 1989
  • Wilcox MH, Finch RG. Is oral acyclovir effective in preventing post-herpetic neuralgia? Infectious Diseases Newsletter 9: 67–68, 1990
  • Editorial. Postherpetic neuralgia. Lancet 336: 537–538, 1990
  • Huff JC, Bean B, Balfour HH, Larkin OL, Connor JD, Corey L, Bryson, YJ, McGuirt P. Therapy of herpes zoster with oral acyclovir. Am J Med 85 ( S2A): 84–89, 1988
  • Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. NZ Med J 102: 93–95, 1989
  • Hope-Simpson RE. Post herpetic neuralgia. J R Coll Gen Pract 25: 571–575, 1975
  • Ragozzino MW, Melton LJ, Kurland LT, Chu CP, Perry HO. Population based study of herpes zoster and its sequelae. Medicine 61: 310–316, 1982
  • Watson CPN. Postherpetic neuralgia. Neurologic Clinics 7: 231–248, 1989
  • Thomson M, Bones M. Non-traditional analgesics for the management of postherpetic neuralgia. Clin Pharm 4: 170–176, 1985
  • Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in post-herpetic neuralgia. Neurology 32: 671–673, 1982
  • Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline but not lorazepam relieves post-herpetic neuralgia. Neurology 38: 1427–1432, 1988
  • Bernstein JE, Bickers DR, Dahl MV, Roshal JY. Treatment of chronic post-herpetic neuralgia with topical capsaicin. J Am Acad Dermatol 17: 93–96, 1987
  • Peterslund NA, Seyer-Hanson K, Ipsen J, Esmann V, Schönheyder H, Juhl H. Acyclovir in herpes zoster. Lancet ii: 827–830, 1981
  • Bean B, Braun C, Balfour HH. Acyclovir therapy for acute herpes zoster. Lancet ii: 118–121, 1982
  • Juel-Jensen BE, Khan JA, Pavsol G. High dose intravenous acyclovir in the treatment of zoster: A double-blind, placebo controlled trial. J Inf 6: 31–36, 1983
  • McGill J, McDonald DR, Fall C, McKendrick GDW, Copplestone A. Intravenous acyclovir in acute herpes zoster infection. J Inf 6: 157–161, 1983
  • Van der Broek PJ, Van der Meer JWM, Mulder JD, Veersteg J, Mattie H. Limited value of acyclovir in the treatment of uncomplicated herpes zoster: A placebo controlled study. Infection 12: 338–341, 1984
  • Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res (in press).
  • Peterslund NA, Esmann V, Ipsen J, Denker Christensen K, Munck Petersen C. Oral and intravenous acyclovir are equally effective in herpes zoster. J Antimicrob Chemother 14: 185–189, 1984
  • McKendrick MW, Care C, Burke C, Hickmott E, McKendrick GDW. Oral acyclovir in herpes zoster. J Antimicrob Chemother 14: 661–665, 1984
  • Wassilew SW, Reimlinger S, Nasemann T, Jones D. Oral acyclovir for herpes zoster: A double-blind controlled trial in normal subjects. Br J Dermatol 117: 495–501, 1987
  • Cobo LM, Foulks GN, Liesegang T, Lass J, Sutphin JE, Wilhelmus K, Jones DB, Chapman S, Segreti AC, King DH. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 93: 763–770, 1986
  • Mandal BL, Dunbar EM, Ellis ME, Ellis J, Dowd P. A double-masked, placebo-controlled trial of acyclovir cream in immunocompromised patients with herpes zoster. J Inf 17: 57–63, 1988
  • “Italian” study-data on file
  • McGill J. Topical acyclovir in herpes zoster ocular involvement. Br J Ophthalmol 65: 542–545, 1981
  • McGill J, Chapman CA. A comparison of topical acyclovir with steroids in the treatment of herpes zoster keratovueitis. Br J Ophthalmol 67: 746–750, 1983
  • SAS Institute Inc, North Carolina, USA.

References

  • Feldman S, Lott L. Varicella in children with cancer: Impact of antiviral therapy and prophylaxis. Pediatrics 80: 465–472, 1987
  • Preblud SR. Varicella: Complications and costs. Pediatrics 78 ( Suppl): 728-–735, 1986
  • Feldhoff CM, Balfour Jr HH, Simmons RL, Najarian JS, Mauer SM. Varicella in children with renal transplants. J Pediatr 98: 25–31, 1981
  • Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2: 1288–1290, 1974
  • Gershon AA, Steinberg SP, Varicella Vaccine Collaborative Study Group of the National Institute of Allergy and Infectious Diseases. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 320: 892–897, 1989
  • Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio MA, LeGore J. Evaluation of varicella-zoster immune globulin: Protection of immunosuppressed children after household exposure to varicella. J Infect Dis 147: 737–743, 1983
  • Balfour Jr HH, Groth KE, McCullough J, Kalis JM, Marker SC, Nesbit ME, Simmons RL, Najarian JS. Prevention or modification of varicella using zoster immune plasma. Am J Dis Child 131: 693–696, 1977
  • Whitley R, Hilty M, Haynes R, Bryson Y, Connor JD, Soong S-J, Alford CA, National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Vidarabine therapy of varicella in immunosuppressed patients. J Pediatr 101: 125–131, 1982
  • Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children – a collaborative study. J Pediatr 101: 622–625, 1982
  • Nyerges G, Meszner Z, Gyarmati E, Kerpel-Fronius S. Acyclovir prevents dissemination of varicella in immunocompromised children. J Infect Dis 157: 309–313, 1988
  • Balfour Jr HH. Intravenous acyclovir therapy for varicella in immunocompromised children. J Pediatr 104: 134–136, 1984
  • Jacobson MA, Berger TG, Fikrig S, Becherer P, Moohr JW, Stanat SC, Biron KK. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 112: 187–191, 1990
  • Cole NL, Balfour Jr HH. Varicella-zoster virus does not become more resistant to acyclovir during therapy. J Infect Dis 153: 605–608, 1986
  • Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection in the renal transplant recipient. Am J Med 70: 405–411, 1981
  • Balfour Jr HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 320: 1381–1387, 1989
  • Balfour Jr HH, Bean B, Laskin OL, Ambinder RF, Meyers JD, Wade JC, Zaia JA, Aeppli D, Kirk LE, Segreti AC, Keeney RE, Burroughs Wellcome Collaborative Acyclovir Study Group. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 308: 1448–1453, 1983
  • Shepp DH, Dandliker PS, Meyers JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients: A randomized comparison of acyclovir and vidarabine. N Engl J Med 314: 208–212, 1986

References

  • Preblud SR. Varicella: Complications and costs. Pediatrics 78 ( Suppl): 728–735, 1986
  • Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9- (2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 74: 5716–5720, 1977
  • Balfour Jr HH, Bean B, Laskin OL, Ambinder RF, Meyers JD, Wade JC, Zaia JA, Aeppli D, Kirk LE, Segreti AC, Keeney RE, Burroughs Wellcome Collaborative Acyclovir Study Group. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 308: 1448–1453, 1983
  • Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children - a collaborative study. J Pediatr 101: 622–625, 1982
  • Nyerges G, Meszner Z, Gyarmati E, Kerpel-Fronius S. Acyclovir prevents dissemination of varicella in immunocompromised children. J Infect Dis 157: 309–313, 1988
  • Bean B, Braun C, Balfour Jr HH. Acyclovir therapy for acute herpes zoster. Lancet ii: 118–121, 1982
  • Balfour Jr HH, Kelly JM, Suarez CS, Heussner RC, Englund JA, Crane DD, McGuirt PV, Clemmer AF, Aeppli DM. Acyclovir treatment of varicella in otherwise healthy children. J Pediatr 116: 633–639, 1990
  • Arvin A, Balfour HH, Dunkle L, Feder H, Feldman S, Gershon A, Levy M, Hayden G, Rotbart H, Whitley R, McGuirt P. The Collaborative Acyclovir-Varicella Study Group. A double-blind, placebo-controlled trial of acyclovir (ACV) treatment of chickenpox in healthy children. In: Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 207, 1990
  • Balfour Jr HH, Dunkle L, Feder H, Feldman S, Goldberg L, Hayden G, Levin M, Prober C, Steinberg S, Whitley R, McGuirt P. The Collaborative Acyclovir-Varicella Study Group. Acyclovir (ACV) therapy of varicella in adolescents. In: Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 207, 1990
  • Al-Nakib W, Al-Kandari S, El-Khalik DMA, El-Shirbiny AM. A randomised controlled study of intravenous acyclovir (Zovirax) against placebo in adults with chickenpox. J Infect 6 ( Suppl I): 49–56, 1983
  • Wallace M, Bowler W, Murray N, Brodine S, Oldfield III E. Oral acyclovir (ACV) in the treatment of adult varicella. In: Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, 207, 1990

References

  • Huang ES, Alford CA, Reynolds DW, Stagno S, and Pass RF. Molecular epidemiology of cytomegalovirus infections in women and their infants. N Engl J Med 303: 958–962, 1980
  • Stagno S, Pass RF, and Dworsky ME. Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection. New Eng J Med 306: 945–949, 1982
  • Ahlfors K, Harris S, Ivarsson S, and Svanberg L. Secondary maternal cytomegalovirus infection causing symptomatic congenital infection. N Eng J Med 305: 284, 1981
  • Rutter D, Griffiths P, and Trompeter R. Cytomegalic inclusion disease after recurrent maternal infection. Lancet ii: 1182, 1985
  • Griffiths PD, Baboonian C, Rutter D, and Peckham C. Congenital and maternal cytomegalovirus infections in a London population. British Journal of Obstetrics and Gynaecology 98: 135–140, 1991
  • Hanshaw JB, Dudgeon JA, and Marshall WC, (Eds). Congenital cytomegalovirus. In: “Viral diseases of the fetus and newborn”, Published Saunders WA 92–131, 1985
  • Ramsey MEB, Miller E, and Peckham CS. Outcome of confirmed symptomatic congenital cytomegalovirus infection. Arch. Dis Child 66: 1068–1069, 1991
  • Pass RF, Stagno S, Myers GJ, and Alford CA. Outcome of symptomatic congenital cytomegalovirus infection: Results of long-term longitudinal follow-up. Pediatrics 66: 758–762, 1980
  • McCracken GH, Shinefield MR, Cobb K, Raunsen AR, Dische MR, and Eichenwald MF. Congenital cytomegalic inclusion disease: A longitudinal study of 20 patients. Am J Dis Child 117: 522–539, 1969
  • Weller TH, and Hanshaw JB. Virologic and clinical observations on cytomegalic inclusion disease. N Eng J Med 266: 1233–1244, 1964
  • Saigal S, Lunyk O, Larke RPB, and Chernesky MA. The outcome in children with congenital cytomegalovirus infection. Am J Dis Child 136: 896–905, 1982
  • Ahlfors K, Ivarsson S, Johnsson T, and Svanberg L. A prospective study on congenital and acquired cytomegalovirus infections in infants. Scand J Infect Dis 11: 177–178, 1979
  • Peckham C, Coleman J, Hurley R, Chin K, and Henderson K. Cytomegalovirus infection in pregnancy: Preliminary findings from a prospective study. Lancet i: 1352–1356, 1983
  • Kumar ML, Nankervis GA, Jacobs IB, Ernhart CB, Glasson CE, McMillan PM, and Gold E. Congenital and postnatally acquired cytomegalovirus infection: Long-term follow up. J Pediatr 104: 674–679, 1984
  • Williamson WD, Desmond MM, LaFevers N, Taber LH, Catlin FI, and Weaver TG. Symptomatic congenital cytomegalovirus: Disorders of language learning and hearing. Am J Dis Child 136: 902–905, 1982
  • Dahle AJ, McCollister FP, Stagno S, Reynolds DW, and Hoffman HE. Progressive hearing impairment in children with congenital cytomegalovirus infection. J of Speech and Hearing Disorders 44: 220–229, 1979
  • Peckham CS, Stark O, Dudgeon JA, Martin JAM, and Hawkins G. Congenital cytomegalovirus infection: A cause of sensorineural hearing loss. Arch Dis Child 62: 1233–1237, 1987
  • Pearl K, Preece P, Ades A, and Peckham C. Neurodevelopmental assessment after congenital cytomegalovirus infection. Arch Dis Child 61: 323–326, 1986
  • Conboy T, Pass R, Stagno S, and Britt W. Intellectual development in school-aged children with asymptomatic congenital cytomegalovirus infection. Pediatrics 77: 801–806, 1986
  • Preece P, Tookey P, Ades A, and Peckham C. Congenital cytomegalovirus infection: Predisposing maternal factors. J Epidemiol Community Health 40: 205–209, 1986
  • Reynolds DW, Stagno S, Hosty TS, Tiller M, and Alford CA. Maternal cytomegalovirus excretion and perinatal infection. N Engl J Med 289: 1–5, 1973
  • Stagno S, Reynolds DW, Pass RF, and Alford CA. Breast milk and the risk of cytomegalovirus infection. N Eng J Med 302: 1073–1076, 1980
  • Peckham CS, Johnson C, Ades A, Pearl K, and Chin KS. The early acquisition of cytomegalovirus infection. Arch Dis Child 62: 780–785, 1987
  • Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, and Bradley JS. Prevention of transfusion-acquired cytomegalovirus infection in newborn infants. J Pediatr 98: 281–287, 1981
  • Stagno S, Brasfield DM, and Brown MB. Infant pneumonitis associated with cytomegalovirus, chlamydia, pneumocystis and ureaplasma - A prospective study. Pediatrics 68: 322–329, 1981
  • Preece P, Pearl K, and Peckham C. Congenital cytomegalovirus. Arch Dis Child 59: 1120–1126, 1984
  • Starr JG, Bart RD, and Gold E. Inapparent congenital cytomegalovirus infection. N Engl J Med 282: 1075–1078, 1970
  • Melish ME, and Hanshaw JB. Congenital cytomegalovirus infection: Developmental progress of infants detected by routine screening. Am J Dis Child 126: 190–194, 1973
  • Alford CA, Stagno S, and Pass RF. Natural history of perinatal cytomegalovirus infection. In: “Perinatal infections”, Ciba Foundation Symposium 77; pp. 125–147, 1980
  • Larke RPB, Wheatley E, Saigal S, and Chernesky MA. Congenital cytomegalovirus infection in an urban Canadian community. J Infect Dis 142: 647–653, 1980
  • Schopfer K, Lauber E, and Krech U. Congenital cytomegalovirus infection in newborn infants of mothers infected before pregnancy. Arch Dis Child 53: 536–539, 1978
  • Andersen HK, Brostrom K, Hansen KB. A prospective study on the incidence and significance of congenital cytomegalovirus infections. Acta Paediat Scand 69: 329–336, 1979
  • Stern H. Cytomegalovirus infection in the neonate and its prevention. Postgrad Med J 55: 588–591, 1977
  • MacDonald H, and Tobin JO. Congenital cytomegalovirus infection: A collaborative study on epidemiological, clinical and laboratory findings. Develop Med Child Neurol 20: 471–482, 1978
  • Peckham CS. Cytomegalovirus in the neonate. J Antimicrobial Chemotherapy 23, Suppl E: 17–21, 1989

References

  • Balfour Jr HH. Cytomegalovirus: The troll of transplantation [Editorial]. Arch Intern Med 139: 279–280, 1979
  • Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush Jr HL, Levey AS, Strom TB, Carpenter CB, Levey RH, Harmon WE, Zimmerman CE, Shapiro ME, Steinman T, LoGerfo F, Idelson B, Schroter GPJ, Levin MJ, McIver J, Leszczynski J, Grady GF. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317: 1049–1054, 1987
  • Winston DJ, Pollard RB, Ho WG, Gallagher JG, Rasmussen LE, Huang SN-Y, Lin C-H, Gossett TG, Merigan TC, Gale RP. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med 97: 11–18, 1982
  • Weimar W, Schellekens H, Lameijer LDF, Masurel N, Edy VG, Billiau A, de Somer P. Double-blind study of interferon administration in renal transplant recipients. Eur J Clin Invest 8: 255–258, 1978
  • Cheeseman SH, Rubin RH, Stewart JA, Tolkoff-Rubin NE, Cosimi AB, Cantell K, Gilbert J, Winkle S, Herrin JT, Black PH, Russell PS Hirsch MS. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. N Engl J Med 300: 1345–1349, 1979
  • Hirsch MS, Schooley RT, Cosimi AB, Russell PS, Delmonico FL, Tolkoff-Rubin NE, Herrin JT, Cantell K, Farrell M-L, Rota TR, Rubin RH. Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal transplant recipients. N Engl J Med 308: 1489–1493, 1983
  • Kovarik J, Mayer G, Pohanka E, Schwarz M, Traindl O, Graf H, Smolen J. Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Transplantation 45: 402–405, 1988
  • Parks WP, Rapp F. Prospects for herpesvirus vaccination - safety and efficacy considerations. Progr Med Virol 21: 188–206, 1975
  • Betts RF. Cytomegalovirus vaccine in renal transplants. Ann Intern Med (Editorial) 91: 780–781, 1979
  • Osborn JE. Cytomegalovirus: Pathogenicity, immunology, and vaccine initiatives. J Infect Dis 143: 618–630, 1981
  • Balfour Jr HH, Welo PK, Sachs GW. Cytomegalovirus vaccine trial in 400 renal transplant candidates. Transplant Proc 17: 81–83, 1985
  • Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, Tustin NB, Grossman R, Dafoe D, Barker C. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. Ann Intern Med 114: 525–531, 1991
  • Elion GB. Mechanism of action and selectivity of acyclovir. Am J Med 73 ( Suppl 1A): 7–13, 1982
  • Balfour Jr HH. Acyclovir. In Peterson PK, Verhoef J, eds. The Antimicrobial Agents Annual/1. Elsevier Science Publications, New York, pp. 322–334, 1986
  • Balfour Jr HH, Vicary CA, Chace BA. Acyclovir suppresses reactivation of cytomegalovirus after marrow transplantation (abstr). Clin Res 34: 962, 1986
  • Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA, Flournoy N, Kirk LE, Kersey JH, Thomas D, Balfour Jr HH. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 318: 70–75, 1988
  • Fletcher CV, Chinnock BJ, Chace B, Balfour Jr HH. Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation. Clin Pharmacol Ther 44: 158–163, 1988
  • Balfour Jr HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 320: 1381–1387, 1989
  • Fletcher CV, Englund JA, Edelman CK, Gross CR, Dunn DL, Balfour Jr HH. The pharmacologic basis for high-dose oral cyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother 35: 938–943, 1991
  • Davis CL. The prevention of cytomegalovirus disease in renal transplantation. Am J Kid Dis 16: 175–188, 1990
  • Balfour Jr HH. Options for prevention of cytomegalovirus disease. Ann Intern Med [Editorial] 114: 598–599, 1991

References

  • Sixbey JW, Nedrud JG, Raab-Traub M, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. New Engl J Med 310: 1225–1234, 1984
  • Sixbey JW, Lemon SM, Pagano, JS. A second site for Epstein-Barr virus shedding: The uterine cervix. Lancet. 2: 1122–1124, 1986
  • Wolf H, Haus M, Wilmes E. Persistence of Epstein-Barr virus in the parotid gland. J Virol 51: 795–798, 1984
  • Fermand JP, Gozlan J, Bendelac A, Delauche-Cavallier MC, Brouet JC, Morinet F. Detection of Epstein-Barr virus in epidermal skin lesions of an immunocompromised patient. Annals of Int Med 112: 511–515, 1990
  • Greenspan JS, Greenspan D, Lennette ET, Abrams DL, Conant MA, Petersen V, Freese K. Replication of Epstein-Barr virus within the epithelial cells of oral “hairy” leukoplakia, an AIDS-associated lesion. New Engl J Med 313: 1564–1570, 1986
  • Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet I: 702–703, 1964
  • Littler E, Baylis SA, Zeng Y, Conway, MJ, Mackett M, Arrand JR. Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. Lancet 337: 685–689, 1991
  • Leyvraz S, Henle W, Chahinian AP, Perlmann C, Klein G, Gordon RE, Rosenblum M, Holland JF. Association of Epstein-Barr virus with thymic carcinoma. N Engl J Med 312: 1296–1299, 1985
  • Henle G, Henle W. The virus as the etiologic agent of infectious mononucleosis. In: Epstein MA, Achong BG, eds. The Epstein-Barr virus. Berlin, Heidelberg, New York: Springer Verlag, 297–320, 1979
  • Chang RS. Clinical manifestations. In: Hall GL, ed.Infectious mononucleosis. Boston, Massachusetts, USA: Medical Publishers, 51–69, 1980
  • Carter R. Infectious mononucleosis: A model for self-limiting lympho-proliferation. Lancet 1: 846–849, 1975
  • Hoagland RJ. The clinical manifestations of infectious mononucleosis; a report of two hundred cases. Am J Med Sci 240: 55–62, 1960
  • Cheeseman SH. Infectious mononucleosis. Semin Hematol 25: 261–268, 1988
  • Mroczek EC, Weisenburger DD, Lipscomb Grierson H, Markin R, Purtilo DT. Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome. Arch Pathol Lab Med 111: 530–535, 1987
  • Isaacs R. Chronic infectious mononucleosis. Blood 3: 858–861, 1948
  • Tobi M, Ravid Z, Feldman-Weiss V, . Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection. Lancet 1: 61–64, 1982
  • Henle W, Henle G, Andersson J, Ernberg I, Marklund G, Horwitz CA, Klein G. Antibody responses to Epstein-Barr virus determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci USA 84: 570–574, 1987
  • Pagano JS. Detection of Epstein-Barr virus with molecular hybridization techniques. Reviews of Infectious Diseases 13 ( Suppl 1): 123–128, 1991
  • Markin RS, Linder J, Zuerlin K. Hepatitis in fatal infectious mononucleosis. Gastroenterology 93: 1210–1217, 1987
  • Andersson J, Ernberg I. Management in Epstein-Barr virus infections. Am J Med 88 ( Suppl 2A): 108–115, 1988
  • Linde A, Kallin B, Dillner J, Andersson J, Jägdahl L, Lindvall A, Wahren B. Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Inf Dis 161: 903–909, 1990
  • Falk K, Ernberg I, Sakthivel R, Davis J, Christensson B, Luka J, Okano M, Grierson HL, Klein G, Purtilo DT. Expression of Epstein-Barr virus-encoded proteins and B-cell markers in fatal infectious mononucleosis. Int J Cancer 46: 976–984, 1990
  • Wolinsky S, Andersson J, Rowley A. Detection of a highly conserved region of herpes viridae DNA by in vitro enzymatic amplification: Application to the detection of a new human herpes virus. In: Immunobiology and Prophylaxis of Human Herpes Virus Infections, eds. Lopes, C. and Whitley R., Plenum, New York, p 219–229, 1990
  • Bender CE. The value of corticosteroids in the treatment of infectious mononucleosis. JAMA 199: 529–531, 1967
  • Bolden KJ. Corticosteroids in the treatment of infectious mononucleosis. J R Coll Gen Pract 22: 87–95, 1972
  • Hedström SÅ. Treatment of anginose infectious mononucleosis with metronidazole. Scand J Infect Dis 12: 265–269, 1980
  • Pagano JS, Sixbey JW, Lin J-C. Acyclovir and Epstein-Barr virus infection. J Antimicrob Chemother 12 ( Suppl B): 113–121, 1983
  • Andersson J, Britton S, Ernberg I, Äkerlund B, Sköldenberg B, Henle W. Effect of acyclovir on infectious mononucleosis. A double-blind, placebo-controlled study. J Infect Dis 153: 283–290, 1986
  • Andersson J, Sköldenberg B, Henle W, Åkerlund B, Ernberg I, Örtquist Å. Acyclovir treatment in infectious mononucleosis: A clinical and virological study. Infection 15 ( Suppl 1): 14–21, 1987
  • Hugo H, Linde A, Åbom P-E. Epstein-Barr virus induced thrombocytopenia treated with intravenous acyclovir and immunoglobulin. Scand J Infect Dis 21: 103–105, 1989
  • Grierson H, Purtilo DT. Epstein-Barr virus infections in males with the X-linked lymphoproliferative syndrome. Ann Intern Med 106: 538–545, 1987
  • Henter JI, Elinder G. Familiar hemophagocytic lymphohistiocytosis. Clinical review based on findings in seven children. Acta Paediatr Scand 80: 269–277, 1991
  • Joab I, Triki H, de Saint Martin J, Perricaudet M, Nicolas JC. Detection of Anti-Epstein-Barr virus trans-activator (ZEBRA) antibodies in sera from patients with human immunodeficiency virus. J Infect Dis 163: 53–56, 1991
  • Morris J, Rosen M, Marchevsky A, Teirstein A. Lymphocytic interstitial pneumonia in patients at risk for the acquired immune deficiency syndrome. Chest 91: 63–67, 1987
  • Schöfer H, Ochsendorf FR, Helm EB, Millbrandt R. Treatment of oral “hairy” leukoplakia in AIDS patients with vitamin A acid (topically) or acyclovir (systemically). Dermatologica 174: 150–151, 1987
  • Pluda JM, Yarchoan R, Jaffe ES, Feuerstein IM, Solomon D, Steinberg SM, Wyvill KM, Raubit-schek A, Katz D, Broder S. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Annals of Int Med 113: 276–282, 1990
  • Ho M, Miller G, Atchison RW, . Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection. J Infect Dis 152: 876–886, 1985
  • Hanto DW, Najarian JS. Advances in the diagnosis and treatment of EBV-associated lymphoproliferative diseases in immunocompromised hosts. J Surg Oncol 30: 215–220, 1985
  • Ferry JA, Jacobson JO, Conti D, Delmonico F, Harris NL. Lymphoproliferative disorders and hematologic malignancies following organ transplantation. Mod Pathol 2: 583–592, 1989
  • Henle W, Henle G. Epstein-Barr virus and human malignancies. In: Klein G, ed.Advances in viral oncology 5. New York: Raven Press, 201–238, 1985
  • Young LS, Dawson CW, Clark D, . Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69: 1051–1065, 1988
  • Jones JF, Shurin S, Abramowsky C, Tubbs RR, Sciotto CG, Wahl R, Sands J, Gottman D, Katz BZ, Sklar J. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infetions. N Engl J Med 318: 733–741, 1988
  • Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337: 320–322, 1991
  • Cuomo L, Trivedi P, Wang F, Winberg G, Klein G, Masucci MG. Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen (LMP) increases the stimulatory capacity of EBV-negative B-lymphoma lines in allogeneic mixed lymphocyte cultures. Eur J Immunol 20: 2293–2299, 1990
  • Hellinger WC, Smith TF, Van Scoy RE, Spitzer PG, Forgacs P, Edson RS. Chronic fatigue syndrome and the diagnostic utility of antibody to Epstein-Barr virus early antigen. JAMA 260: 971–973, 1988
  • Straus SE, Dale JK, Tobi M, Lawley T, Preble O, Blaese RM, Hallahan C, Henle W. Acyclovir treatment of the chronic fatigue syndrome: Lack of efficacy in a placebo-controlled trial. N Engl J Med 319: 1692–1698, 1988
  • Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med 89: 561–568, 1990
  • Peterson PK, Shepard J, Macres M, Schenck C, Crosson J, Rechtman D, Lurie N. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med 89: 554–560, 1990

References

  • Thomson BJ, Martin MED, Honess RW. The molecular and biological properties of human herpesvirus 6 (HHV-6), pp. 163–184, In: AG Dalgleish, RA Weiss (eds), AIDS and the new viruses, Academic Press, NY 1990
  • Lawrence GL, Chee M, Craxton MA, Gompels UA, Honess RW, Barrell BG. Human herpesvirus 6 is closely related to human cytomegalovirus. J Virol 64: 287–299, 1990
  • Salahuddin SZ, Ablashi DV, Markham PD, Josephs SF, Sturzenegger S, Kaplan M, Halligan G, Biberfeld P, Wong-Staal F, Kramarsky B, Gallo RC. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 234: 596–601, 1986
  • Levy JA, Ferro F, Greenspan D, Lennette ET. Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population. Lancet 335: 1047–1050, 1990
  • Black JB, Sanderlin KC, Goldsmith CS, Gary HE, Lopez C, Pellett PE. Growth properties of human herpesvirus-6 strain Z29. J Virol Meth 26: 133–146, 1989
  • Lusso P, Markham PD, Tschachler E, di Marzo Veronese F, Salahuddin SZ, Ablashi DV, Pahwa S, Krohn K, Gallo RC. In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6). J Exp Med 167: 1659–1670, 1988
  • Lusso P, Gallo RC, DeRocco SE, Markham PD. CD4 is not the membrane receptor for HHV-6. Lancet i: 730, 1989
  • Linde A, Dahl H, Wahren B, Fridell E, Salahuddin Z, Biberfeld P. IgG antibodies to human herpesvirus-6 in children and adults and in primary Epstein-Barr virus and cytomegalovirus infections. J Virol Meth 21: 117–123, 1988
  • Dahl H, Linde A, Sundqvist VA, Wahren B. An enzyme-linked immunosorbent assay for IgG antibodies to human herpes virus 6. J Virol Meth 29: 313–324, 1990
  • Linde A, Fridell E, Dahl H, Andersson J, Biberfeld P, Wahren B. Effect of primary Epstein-Barr virus infection on human herpesvirus 6, cytomegalovirus, and measles virus immunoglobulin G titers. J Clin Microbiol 28: 211–215, 1990
  • Yamanishi K, Okuno T, Shiraki K, Takahashi M, Kondo T, Asano Y, Kurata T. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet i: 1065–1067, 1988
  • Farr TJ, Harnett GB, Pietroboni GR, Bucens MR. The distribution of antibodies to HHV-6 compared with other herpesviruses in young children. Epidemiol Infect 105: 603–607, 1990
  • Holmes GP, Kaplan JE, Stewart JA, Hunt B, Pinsky PF, Schonberger LB. A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause? JAMA 257: 2297–2302, 1987
  • Niederman JC, Liu CR, Kaplan MH, Brown NA. Clinical and serological features of human herpesvirus-6 infection in three adults. Lancet ii: 817–819, 1988
  • Irving WL, Cunningham AL. Serological diagnosis of infection with human herpesvirus type 6. Br Med J 300: 156–159, 1990
  • Ensoli B, Lusso P, Schachter F, Josephs SF, Rappaport J, Negro F, Gallo RC, Wong-Staal F. Human herpes virus-6 increases HIV-1 expression in co-infected T cells via nuclear factors binding to the HIV-1 enhancer. EMBO J 8: 3019–3027, 1989
  • Åkesson-Johansson A, Harmenberg J, Wahren B, Linde A. Inhibition of human herpesvirus 6 replication by 9-/4-hydroxy-2-(hydroxy-methyl) butyl/guanine (2HM-HBG) and other antiviral compounds. Antimicrob Agents Chemother 34: 2417–2419, 1990
  • Streicher HZ, Hung CL, Ablashi DV, Hellman K, Saxinger C, Fullen J, Salahuddin SZ. In vitro inhibition of human herpesvirus-6 by phosphonoformate. J Virol Meth 21: 301–304, 1988

References

  • Morein B, Simons K. Subunit vaccines against enveloped viruses: Virosomes, micelles and other protein complexes. Vaccine 3: 83–93, 1985
  • Morein B, Höglund S. Subunit vaccines against infection by enveloped viruses. In: Viral Vaccines. Wiley-Liss Inc. New York, pp. 69–90, 1990
  • Bcran GW, Bryan Davies E. Arambulo Primo V. Persistance of pseudorabies virus in infected swine. J Am Vet Med Assoc 176: 998–1000, 1980
  • Andrees K, Pensaert MB, Vandeputte J. Effect of experimental infection with pseudorabies (Aujcszky's disease) virus on pigs with maternal immunity from vaccinated sows. Am J Vet Res 39: 1282–1285, 1978
  • Morein, B, Belák, S, Sóos, T, Rusvai, M, McGwire, BS, Morein B, Bonár G. Iscom of viral envelope proteins protects against Aujeszky's disease. Vet Microbiol 20: 143–154, 1989
  • Trudel M, Boylay G, Seguin C, Nadon F, Lussin G. Control of infectious bovine rhinotracheitis in calves with BHV-1 subunit iscom vaccine. Vaccine 6: 525–529, 1988
  • Trudel M, Nadon F, Séguin C, Simard C, Lussier G. Experimental polyvalent iscoms subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus. Vaccine 7: 12–16, 1989
  • McRza M, Belák S, Morein B. Characterization of an iscom prepared with enveloped glycoproteins of bovine herpesvirus type 1. J Vet Med B 35: 695–703, 1988
  • Babuik LA, Litalien J, Van Drunen Little S, Van Den Hurk, Zamb T, Lowman MJP, Hughes G, Gifford GA. Protection of cattle from Bovine herpesvirus type 1 (BHV-1) infection by immunization with individual viral glycoproteins. Virology 159: 57–66, 1987
  • McRza M, Sóos T, Kuchera L, Bognar G, Morein, B. Iscom of BHV-1 envelope glycoproteins protected calves against both disease and infection. In press, J Vet Med B. 38, 306–314 (1991).
  • Alexander TS, Rosenthal KS. Autologous antibody is protective against HSV-1 infection of the immunocompromised mouse. J Lab Clin Med 116: 400–407, 1990
  • Kohl S, Loo LS, Drath DB, Cox, P. Interleukin-2 protects neonatal mice from lethal Herpes simplex virus infection: A macrophage-mediated, gamma interferon-induced mechanism. J Inf Dis 159: 239–247, 1989
  • McDermott MR, Goldsmith CH, Rosenthal KL, Brais LJ. T-lymphocytes in genital lymph nodes protect mice from intravaginal infection with herpes simplex virus type 2. J Infect Dis 159: 460–466, 1989
  • Rodney JHHO, Burke RL, Merigan TC. Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs. J virol. 63: 2951–2958, 1989
  • Igietseme JU, Streilein JW, Miranda F, Feinerman SJ, Atherton SS. Mechanisms of protection against herpes simplex virus type 1 - Induced retinal necrosis by in vitro-activated T-lymphocytes. J Virol 65: 763–768, 1991
  • Feduchi E, Carrasco L. Mechanism of inhibition of HSV-1 replication by tumour necrosis factor and interferon-gamma. Virology 180, 822–825, 1991
  • Blacklaws BA, Nash AA. Immunological memory Herpes simplex virus type 1 glycoproteins B and D in mice. J Gen Virol 71: 863–871, 1990
  • Weir JP, Bennet M, Allen EM, Elins KL, Martin S, Rouse BT. Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge. J Gen Virol 70: 2587–2594, 1989
  • Broker M, Abel K, Kohler R, Hilfenhaus J, Amann E. Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protect mice against a lethal challenge with HSV-1 and HSV-2. Med Microbiol Immunol 179: 145–159, 1990
  • Ertürk ME, Jennings R, Hockley D, Potter CW. Antibody responses and protection in mice immunized with Herpes simplex virus type 1 antigen immune-stimulating complex preparations. J Gen Virol 70: 2149–2155, 1989
  • Ertürk ME, Pillpots RJ, Welch MJ, Jennings R. Efficacy of HSV-1 iscom vaccine in the guineapig model of HSV-2 infection. In press, Vaccine
  • Ertürk ME. Studies on primary infection and establishment of latency following HSV-1 infection models in mice previously immunized with HSV-1 antigen preparations. In manuscript.
  • Wahren B, Nordlund S, Åkesson A, Sundquist B, Morein B. Monocyte and iscom enhancement of cell-mediated response versus cytomegalovirus. Med Microbiol Immunol 176: 13–17, 1987
  • Okazaki W, Purchase HG, Burmester BR. Protection against Marek's disease by vaccination with a herpesvirus of turkeys. Avian Dis 14: 413–429, 1970
  • Purchase HG, Okazaki W, Burmester BR. Long-term trials with the herpesvirus of turkeys vacine against Marek's disease. Avian Dis 16: 57–71, 1972
  • Shanmugaratnam K. Studies on the etiology of nasopharyngeal carcinoma. In: International review of experimental pathology. Ed. by GW Richter & MA Epstein. New York & London: Academic Press, pp. 361–413, 1971
  • Burkitt DA. Lymphoma syndrome in tropical Africa. In: International Review of Experimental Pathology. Richter GW, Epstein MA. (Eds) New York & London: Academic Press, pp. 67–138, 1963
  • Cleary ML, Epstein MA, Finerty S, Dorfman RF, Bornkamm GW, Kirkwood JK, Morgan AJ, Skdar J. Individual tumours of multifocal EB virus-induced malignant lymphoma in tamarins arise from different B-cell clones. Science 228: 722–724, 1985
  • Dorfman RF, Burke JS, Berard C. A working formulation of non-Hodgkins lymphomas, background recommendations, histological criteria, and relationship to other classifications. In: Malignant Lymphomas. Ed. Rosenberg & Kaplan. Academic Press N.Y. pp. 351–368, 1982
  • Morgan AJ, Finerty S, Lövgren K, Scullion Ft, and Morein B. Prevention of Epstein-Barr (EB) virus induced lymphoma in cottontop tamarins by vaccination with EB virus envelope glycoprotein gp340 incorporated into iscom. J. Gen. Virol 69: 2093–2096, 1988
  • Speijers GJA, Danse LHJ, Beuvery EC, Strik JJTWA, Vos JG. Local reactions of the saponin Quil A and a Quil A containing iscom measles vaccine after intramuscular injection of rats: A comparison with the effect of DPT-polio vaccine. Fund Appl Toxicol 10: 425–430, 1988
  • Watson DL, Lövgren K, Watson NA, Fossum C, Morein B and Höglund S. Inflammatory response and antigen localization following immunization with influenza virus iscoms. Inflammation 13: 641–649, 1989
  • Fossum C, Bergström M, Lövgren K, Watson DL, Morein B. Effect of iscom and/or their adjuvant moiety (matrix) on the initial proliferative and IL-2 responses in vitro. Comparison of spleen cells from mice inoculated with iscoms and/or matrix. Cell Immunol 129: 414–425, 1990
  • Ulaeto D, Wallace L, Morgan A, Morein B, Rickinson A. In vitro T-cell responses to a candidate Epstein-Barr virus vaccine: Human CD4+ T-cell clones specific for the major envelope glycoprotein gp340. Eur J Immunol 18: 1689–1697, 1988
  • Bejarano MT, Masucci MG, Morgan A, Morein B, Klein G, Klein EJ. Epstein-Barr virus (EBV) antigens processed and presented by B-cells, B-blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation. J Virol 64: 1398–1401, 1990
  • Watson DL, Watson NA, Fossum C, Lövgren K, Morein B. Mechanisms of immunogenicity of iscoms - evidence from antibody responses and interactions with peritoneal mononuclear leucocytes. Submitted.
  • Lövgren K. The serum antibody response distributed in subclasses and isotypes after intra-nasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand J Immunol 27: 241–245, 1988
  • Lövgren K, Kåberg H, Morein B. An experimental influenza subunit vaccine (iscom): Induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. Clin Exp Immunol 82: 435–439, 1990
  • Jones PD, Tha Hla R, Morein B, Ada GL. Cellular immune responses in the murine lung to local immunzation with influenza A virus glycoproteins in micellses and immunostimulatory complexes (iscoms). Scand J Immunol 27: 645–652, 1988
  • Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. Induction of specific CD8+ class IMHC restricted CTL against HIV envelope protein by immunization with purified whole proteinin iscoms. Nature 344: 873–875, 1990

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.